ImmunityBio, Inc. Overview
Pro stress-test →ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. ANKTIVA® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer that activates natural killer cells, T cells, and memory T cells for a long-duration response.
Strategic Profile
Pro stress-test →The company has triple-digit revenue growth and a dominant position in the IL-15 landscape, representing an active disruptor in the oncology market. ImmunityBio positions ANKTIVA as a combination partner for existing therapies like Merck's Keytruda, effectively "co-opting" the market share of established blockbusters rather than competing solely on a head-to-head basis. The company has established strategic partnerships to drive the commercialization of Anktiva in the EU and MENA regions, expanding its global footprint.
Competitive Landscape
Pro stress-test →ImmunityBio positions ANKTIVA as a combination partner for existing blockbuster therapies like Merck's Keytruda rather than competing solely on a head-to-head basis. The company competes within the immuno-oncology space alongside cell therapy specialists and established pharma companies developing checkpoint inhibitors. The increasing prevalence of cancer and the growing demand for immunotherapies offer significant opportunities for the company.
Industry Context
ImmunityBio, Inc. operates in Biotechnology - Immuno-Oncology and Cell Therapy.
Key facts
Founded: 2021 (merged form) · Headquarters: San Diego, California · Revenue: $113M (2025) · Market cap: $7.2B